Quince Therapeutics (QNCX) The ThinkEquity Conference 2024 summary

Clinical program highlights

• Pivotal Phase III NEAT trial of EryDex for ataxia-telangiectasia (A-T) is underway, with topline results expected in Q4 2025 and cash runway into early 2026.

• The phase III study is risk-mitigated with FDA Special Protocol Assessment, Fast Track, and Orphan Drug Designation, enabling faster progress and cost savings.

• The study focuses on 6- to 9-year-old patients, leveraging prior data showing efficacy in this subgroup.

• An open-label extension and label expansion for older patients are underway.

• Prior Phase 3 ATTEST study showed EryDex was well-tolerated and improved outcomes in A-T patients.

Technology and therapeutic approach

• EryDex uses proprietary AIDE technology to encapsulate dexamethasone in autologous red blood cells, enabling monthly infusions with unique biodistribution and reduced steroid side effects.

• Over 270 patients have received EryDex, with nearly 6,000 doses administered and no serious safety concerns or typical steroid side effects observed.

• The device is CE marked in Europe, with IP protection extending globally to 2034 and in the U.S. to 2035.

• The process is fully automated, takes 1.5 hours, and is designed for scalability and flexibility across therapeutic classes.

• Over $100 million has been invested in AIDE technology development.

Market opportunity and commercial strategy

• EryDex targets a $1+ billion global peak commercial opportunity for A-T, with an estimated 10,000 patients in the U.S., U.K., and major European countries.

• No approved treatments exist for A-T, and EryDex has first-to-market potential with no known late-stage competition.

• Pricing is benchmarked against Skyclarys ($370,000/year), with cost of goods under 1%.

• Commercial rollout will begin in centers of excellence and infusion centers, with potential for mobile delivery in rural areas.

• Plans include exploring partnerships, out-licensing opportunities, and potential out-licensing of ex-U.S. territories.